Anzeige
Mehr »
Login
Samstag, 29.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 896047 | ISIN: US09058V1035 | Ticker-Symbol: BO1
Frankfurt
28.03.25
09:15 Uhr
7,184 Euro
-0,028
-0,39 %
1-Jahres-Chart
BIOCRYST PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
BIOCRYST PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,1907,25028.03.
7,1867,34428.03.

Aktuelle News zur BIOCRYST PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.03.BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)95RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted...
► Artikel lesen
05.03.BIOCRYST - CFO schmeißt hin! Grund zur Sorge?3
BIOCRYST PHARMACEUTICALS Aktie jetzt für 0€ handeln
04.03.BioCryst falls 8% following CFO departure announcement14
04.03.BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report-
03.03.BioCryst stock holds $18 target, JMP bullish on trial results1
25.02.BIOCRYST PHARMACEUTICALS INC - 10-K, Annual Report2
25.02.H.C. Wainwright maintains Buy on BioCryst stock, $30 target5
25.02.BioCryst stock holds Market Outperform amid new targets1
25.02.Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today2
24.02.Piper Sandler maintains BioCryst stock Overweight with $23 target1
24.02.BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings2
24.02.BioCryst stock drops following Q4 earnings miss1
24.02.BioCryst-Aktie fällt nach enttäuschenden Quartalsergebnissen2
24.02.JPMorgan maintains BioCryst stock with $10 target, upbeat on growth2
24.02.BioCryst Pharma Posts Narrower Loss In Q4; Raises FY25 ORLADEYO Revenue Guidance3
24.02.Earnings Snapshot: BioCryst Pharmaceuticals revenue surpasses estimates, EPS misses at -$0.13; raises FY25 outlook3
24.02.BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS2
24.02.BioCryst Pharmaceuticals reports mixed Q4 results; updates FY25 outlook7
24.02.BioCryst Pharmaceuticals, Inc.: BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones244-ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)- -FY 2025 ORLADEYO net revenue guidance increased to between $535-$550...
► Artikel lesen
24.02.BioCryst Pharmaceuticals, Inc.: BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years99-Additional real-world studies with ORLADEYO show statistically significant HAE attack rate reductions experienced by patients with C1-INH deficiency and normal C1-INH levels and function- -Data will...
► Artikel lesen
Seite:  Weiter >>
71 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1